See how SPIRIVA® is successful in reducing exacerbations in your patients like Olivia
image description

Olivia is successful in her business.

See the success of SPIRIVA® in reducing her risk of COPD exacerbations

A wealth of COPD exacerbations data demonstrating the strong efficacy of SPIRIVA®1-3*

SPIRIVA® Respimat® delivered consistent results in reducing risk of COPD exacerbations compared with control, measured in time to exacerbation1

31% reduced risk vs control in time to first COPD exacerbation (p<0.001)

Time to first COPD exacerbation

27% reduced risk vs control in time to first COPD exacerbation resulting in hospitalization (p<0.005)

Time to first COPD exacerbation resulting in hospitalisation

SPIRIVA® delivered consistent results in reducing risk of COPD exacerbations compared with control, measured in time to exacerbation2§||

33% increase in time to first exacerbation vs control

In time to first COPD exacerbation

14% reduced risk of severe COPD exacerbations leading to hospitalization vs control

For severe COPD exacerbations leading to hospitalisation

Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®. SPIRIVA® did not alter the rate of decline in lung function, a coprimary endpoint in the UPLIFT® trial.

SPIRIVA® delivered consistent results in reducing risk of COPD exacerbations compared with salmeterol MDI

17% reduced risk in time to first COPD exacerbation vs salmeterol (p<0.001)

Time to first COPD exacerbation

28% increase in time to first COPD exacerbation resulting in hospitalization vs salmeterol (p<0.001)

Time to first COPD exacerbation resulting in hospitalisation

SPIRIVA® helps manage your COPD patients' exacerbation risk4-6||

In sub-analyses of UPLIFT® and
POET-COPD®

SPIRIVA® prolongs time to first exacerbation; helps patients maintain low-risk status; and, by reducing the frequency of exacerbations, helps shift high-risk patients to low-risk without ICS use

Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®. SPIRIVA® did not alter the rate of decline in lung function, a coprimary endpoint in the UPLIFT® trial.

  • Helped patients maintain their low-risk status by prolonging the time to first COPD exacerbation‡‡
  • Helped shift high-risk patients to low-risk status by reducing the number of COPD exacerbations§§

SPIRIVA® provides efficacy without ICS use, reducing potential related side effects4,5

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler® or SPIRIVA® Respimat® 2.5 µg (two puffs, once daily).
HR=0.69 (95% CI=0.63, 0.77).
HR=0.73 (95% CI=0.59, 0.90).
§Data presented refer to once-daily SPIRIVA® 18 µg via HandiHaler®.
||SPIRIVA® 18 µg via HandiHaler® did not alter the rate of decline in lung function, a coprimary study endpoint in the UPLIFT® trial.
RR=0.78 (95% CI=0.67, 0.92), p=0.003.
#HR=0.86 (95% CI=0.78, 0.95), p=0.002.
**HR=0.83 (95% CI=0.77, 0.90).
††HR=0.72 (95% CI=0.61, 0.85).
‡‡After 1 year, SPIRIVA® 18 µg via HandiHaler® was associated with a lower risk of transitioning from a low-risk to a high-risk status vs placebo.
§§After 1 year, SPIRIVA® 18 µg via HandiHaler® was associated with a bigger shift of patients from high-risk to low-risk vs placebo.

References
1. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460-1472. 2. Tashkin DP, Celli B, Senn S, et al; for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554. 3. Vogelmeier C, Hederer B, Glaab T, et al; for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103. 4. Celli BR, Decramer M, Asijee GM, Kupas K, Taskin DP. Effects of tiotropium on exacerbations in patients with COPD with low or high risk of exacerbations: a post-hoc analysis from the 4-year UPLIFT® trial. J COPD Found. 2015;2(2):122-130. 5. Global initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; Updated 2016. www.goldcopd.org. Accessed January 5, 2016. 6. Hurst JR, Vestbo J, Anzueto A, et al; for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.